Please assess the completion status of the following clinical trial:

Trial Title: Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of clear cell renal cell carcinoma~  * Metastatic disease~* Measurable disease~* Previously treated with high-dose aldesleukin OR not eligible for or refused such therapy~* No brain metastases by MRI or CT scan~* HLA-partially matched (e.g., ≥ 2/6 HLA A, B, Dr match) related donor available~  * Patients who have no partially matched immediate family member available are eligible if they have a fully HLA-matched donor~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Bilirubin ≤ 2 times upper limit of normal~* Creatinine clearance ≥ 40 mL/min~* AST ≤ 3 times ULN~* Cardiac ejection fraction ≥ 45%~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Irradiated allogeneic lymphocytes (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).